CLAIMS

1. Use of a pharmaceutical composition in the manufacture of a medicament for preventing or treating human rhinovirus infection or human influenza virus infection, wherein said composition is to be applied to the nasal or oral mucosa of an individual, the pharmaceutical composition comprising a pharmaceutically acceptable carrier and lactoferrin and lysozyme; wherein said composition does not include sialic acid and/or ICAM-1.

2. The use according to claim 1, the pharmaceutical composition further comprising:

(i) one or more of zinc peroxide, copper, and silver,

(ii) carrageenan;

(iii) one or more ingredients selected from the group consisting of marshmallow extract, calendula extract, citrus peel extract, honey extract, rosemary extract, myrrh extract, Helichrysum extract, arrowroot extract, neem oil, vitamin C, vitamin E, and grapefruit seed extract; or

(iv) citrus peel extract.

3. The use according to claim 1, wherein said composition is in the form of a nasal spray, nasal drops, oral spray, oral rinse, or lozenge.

4. Use of the composition of claim 1 in the manufacture of a medicament for prophylaxis and/or treatment of human rhinovirus infection, wherein the composition is to be administered to the nasal and/or oral mucosa of an individual in need thereof.

5. The use according to claim 4, wherein the nasal and/or oral mucosa of said individual in need thereof has human rhinovirus in contact therewith.

6. Use of the composition of claim 1 in the manufacture of a medicament for the prophylaxis and/or treatment of human influenza virus infection, wherein the composition is to be administered to the nasal and/or oral mucosa of an individual in need thereof.

7. The use according to claim 6, wherein the nasal and/or oral mucosa of said individual in need thereof has human influenza virus in contact therewith.

8. The use according to claim 1, wherein the pharmaceutical composition comprises from 0.5-5000 μg/mL lactoferrin and from 0.5-5000 μg/mL lysozyme.

9. The use according to claim 1, wherein the pharmaceutical composition comprises from 0.0025% to 1% by weight lysozyme and from 0.00005% to 1% by weight lactoferrin.

10. The use according to claim 1, wherein said carrier provides a residence time of the composition on the nasal and/or oral mucosa of at least 1 minute.